PSP Energy Publishes 2026 Corporate Governance Report
Bitget2026/10/30 09:45- PSP Energy published its governance report for the year ended June 30, 2026, with four independent directors on its seven-member board.
- The board has not adopted a strict nine-year independence limit; directors may retain independent status beyond nine years with shareholder approval.
- Group Managing Director Ong Chee Seng and Executive Director Rafidah Binti Bahtiar will seek re-election at the second annual general meeting.
- Ong Chee Seng leads sustainability integration across the group's operations as the designated senior management executive.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.